This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Welcome to Novo Nordisk Rare Diseases Science Hub

 

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a non-US healthcare professional.

Reference not found.

1.

Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: Growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361–397

2.

Brod M, Alolga SL, Beck JF, Wilkinson L, Højbjerre L, Rasmussen MH. Understanding burden of illness for child growth hormone deficiency. Qual Life Res. 2017;26(7):1673–1686.

3.

Backeljauw P, Cappa M, Kiess W, Law L, Cookson C, Sert C, Whalen J, Dattani MT. Impact of short stature on quality of life: A systematic literature review. Growth Horm IGF Res. 2021;57–58:101392.

4.

Høybye C, Cohen P, Hoffman AR, Ross R, Biller BM, Christiansen JS. Status of long-acting-growth hormone preparations--2015. Growth Horm IGF Res. 2015;25(5):201–206.

5.

Novo Nordisk A/S. Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen summary of product characteristics. 2021. https://www.novo-pi.com/sogroya.pdf. Last Updated 10 2021.

6.

Novo Nordisk Inc. Sogroya, somapacitan-beco injection prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761156s000lbl.pdf. Last Updated 08 2020.

7.

Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, Savendahl L. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. Clin Endocrinol (Oxf). 2017;87(4):350–358.

8.

Johannsson G, Feldt-Rasmussen U, Håkonsson IH, Biering H, Rodien P, Tahara S, Toogood A, Rasmussen MH, the RSG, Biering H, Karges W, Mann A, Christiansen JS, Hansen TK, Andersen M, Feldt-Rasmussen U, Borresen S, Rodien P, Borson-Chazot F, Kerlan V, Cariou B, Verges B, Tahara S, Matsuno A, Takano K, Tagami T, Takahashi Y, Takahashi T, Yamamoto M, Johannsson G, Höybye C, Erfurth E-M, Drake W, Higham C, Murray R, Toogood A, Brooke A. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. 2018;178(5):491–499.

9.

Otsuka F, Takahashi Y, Tahara S, Ogawa Y, Rasmussen MH, Takano K. Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone. Clin Endocrinol (Oxf). 2020;93(5):620–628.

10.

Johannsson G, Gordon MB, Højby Rasmussen M, Håkonsson IH, Karges W, Sværke C, Tahara S, Takano K, Biller BMK. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: A randomized phase 3 trial. J Clin Endocrinol Metab. 2020;105(4):e1358–1376.

11.

Sävendahl L, Battelino T, Rasmussen MH, Brod M, Saenger P, and Horikawa R. Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3. J Clin Endocrinol Metab. 2021; Dec 29;dgab928. Online ahead of print.